Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment

Abstract

The development of highly selective and efficient tumor-targeted smart drug delivery nanodevices remains a great challenge in nanomedicine. This work reports the design and optimization of a multifunctional nanosystem based on mesoporous silica nanoparticles (MSNs) featuring selectivity towards human osteosarcoma cells and pH-responsive antitumor drug delivery capability. The novelty and originality of this manuscript relies on proving that the synergistic assembly of different building blocks into a unique nanoplatform increases antitumor effectiveness and decreases toxicity towards healthy cells, which constitutes a new paradigm in targeted bone cancer therapy.

Cancer cell targeting and therapeutic delivery of silver nanoparticles by mesoporous silica nanocarriers: insights into the action mechanisms using quantitative proteomics

“…[14][15][16] MSNs usually show particle diameters in the 50-200 nm range and narrow pore size distributions of 3-6 nm. Their highly ordered pore network is used to store drug molecules, 17,18 and their silanol rich surface provides covalent attachment of organic moieties to the MSNs to impart stealth, targeting [19][20][21] or smart functionalities. [22][23][24] Hence, several studies demonstrate their use in drug delivery, [25][26][27] diagnosis 28 or vaccines, 29,30 among others.…”

Nanotechnology and sialic acid biology

“…ConA-conjugated DOX-loaded mesoporous silica nanoparticles (MSNs) find applications as delivery devices in bone cancer treatment as ConA and can recognize and bind sialic acid overexpressed in human osteosarcoma (HOS) cell line [70].…”

Silica‐based organic‐inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery

“…For instance, traditional MSN drug release systems were not able to distinguish inflammatory tissues, resulting in damage of both inflammatory and healthy tissues [58]. For instance, traditional MSN drug release systems were not able to distinguish inflammatory tissues, resulting in damage of both inflammatory and healthy tissues [58].…”

“…Despite the notable success of external and internal stimuli responsive organic-inorganic hybrid silica nanoparticles, more specific applications were required in cancer therapy such as ligand conjugating strategy as active targeting in order to improve the specificity of nanoparticles towards tumor cells. For instance, traditional MSN drug release systems were not able to distinguish inflammatory tissues, resulting in damage of both inflammatory and healthy tissues [58]. Thus, researchers searched for alternatives to improve the delivery efficiency and cancer specific recognition and focused on active targeting ligands, peptides and antibodies that recognize particular receptors in target cells with subsequent uptake through receptor-mediated endocytosis.…”